The global oligonucleotide synthesis market was valued at USD 2.6 billion in 2025 and is projected to reach USD 5.9 billion by 2032, expanding at a CAGR of 12.4% from 2026 to 2032. Oligonucleotide synthesis refers to the chemical production of short, custom-designed DNA and RNA sequences used as essential molecular building blocks across modern life sciences. These synthetic nucleic acids support a wide range of applications, including molecular diagnostics, genomics research, next-generation sequencing, synthetic biology, gene editing, drug discovery, and nucleic acid-based therapeutics. The market spans oligonucleotide synthesis products and services, reagents and consumables, and equipment, serving pharmaceutical and biotechnology companies, academic and research institutes, contract research organizations, and other end users. As precision medicine and molecular biology become increasingly embedded in healthcare and research workflows, demand is shifting from conventional research-grade oligos toward more complex, modified, and GMP-grade products capable of supporting clinical development and commercial therapeutic manufacturing.

Market expansion is being supported by the growing use of synthetic oligonucleotides in molecular diagnostics and precision medicine, the increasing global burden of cancer, infectious diseases, and genetic disorders, rapid advances in synthetic biology and gene editing, and rising investment in genomics and life sciences R&D. Oligonucleotides are becoming increasingly important in PCR, qPCR, next-generation sequencing, liquid biopsy, companion diagnostics, CRISPR applications, and RNA-based drug development. At the same time, the commercialization of antisense oligonucleotides, siRNA therapeutics, and other nucleic acid-based modalities is increasing demand for high-purity and GMP-grade synthesis capabilities. Technology development is also moving toward automated synthesis, high-throughput production, complex oligo pools, advanced purification, and specialized chemical modifications. North America remains the largest regional market, while Asia Pacific is projected to be the fastest-growing region as biotechnology infrastructure, genomics research, molecular diagnostics, and government-backed R&D investment expand across the region. Over the forecast period, the market is expected to evolve toward higher-complexity synthesis, greater automation, integrated manufacturing, and stronger demand for validated GMP capabilities, while emerging applications in CRISPR screening, synthetic biology, precision medicine, and nucleic acid therapeutics create additional avenues for growth.

Key Highlights of the Report

• In terms of product type, oligonucleotide synthesis dominates the global oligonucleotide synthesis market, supported by the essential role of synthesized DNA and RNA sequences across research, diagnostics, synthetic biology, and therapeutic development workflows.

• Within oligonucleotide synthesis, custom oligonucleotide synthesis represents an important growth area, as pharmaceutical, biotechnology, and research customers increasingly require sequences with specialized modifications, specific purity levels, and application-specific characteristics.

• The equipment segment is projected to record the fastest growth among product type sub-segments, supported by increasing investments in automated synthesis platforms, high-throughput production systems, purification technologies, and analytical instruments required to improve scalability and process consistency.

• In terms of application, research dominates the global oligonucleotide synthesis market, driven by extensive use in gene expression studies, functional genomics, molecular cloning, CRISPR guide RNA design, synthetic biology, and next-generation sequencing workflows.

• The therapeutics segment is projected to record the fastest growth among application categories, supported by expanding pipelines for antisense oligonucleotides, siRNA therapeutics, RNA-based drug candidates, and other nucleic acid-based treatment modalities.

• By end use, pharmaceutical and biotechnology companies dominate the global oligonucleotide synthesis market, reflecting increasing demand throughout the drug development value chain, from target validation and discovery research to clinical manufacturing and commercial-scale production.

• The contract research organization segment is projected to record the fastest growth among end-use categories, supported by increasing outsourcing of drug discovery and preclinical research activities and the growing need for specialized oligonucleotide synthesis capabilities.

• Molecular diagnostics and precision medicine are major demand catalysts, as synthetic oligonucleotides serve as primers, probes, sequencing adapters, hybridization capture reagents, and other essential components of advanced diagnostic workflows.

• The market is benefiting from rapid advances in synthetic biology and gene editing, with CRISPR-based research, engineered genetic circuits, genome engineering, and synthetic gene construction increasing demand for highly accurate and customized oligonucleotides.

• High-complexity oligo pools represent an emerging opportunity, particularly for synthetic biology, CRISPR screening, functional genomics, and large-scale genomic research requiring thousands to millions of unique sequences.

• Demand for GMP-grade oligonucleotide synthesis is increasing, supported by the expanding clinical and commercial pipeline of nucleic acid therapeutics and the need for validated manufacturing processes, stringent quality control, and reliable supply chains.

• The growing prevalence of cancer, infectious diseases, and genetic disorders is supporting market expansion, as healthcare and research organizations increasingly rely on molecular diagnostics, biomarker identification, and targeted therapeutic approaches.

• By region, North America dominates the global oligonucleotide synthesis market, primarily driven by its established pharmaceutical and biotechnology ecosystem, extensive research infrastructure, strong federal funding, and presence of major synthesis providers.

• Asia Pacific is projected to be the fastest-growing regional market, supported by expanding biotechnology infrastructure, growing molecular diagnostics adoption, rising R&D investment, and increasing research activity across China, India, Japan, South Korea, and Australia.

• The competitive landscape is moderately concentrated, with Thermo Fisher Scientific leading the market, followed by major participants including Eurofins, GenScript, Merck, and Agilent Technologies. The leading five companies collectively accounted for approximately 55% of market revenue in 2025.

• The market is increasingly shifting toward quality, regulatory compliance, and supply chain reliability, particularly for pharmaceutical customers requiring GMP-grade materials for clinical and commercial therapeutic programs.

• Stringent government regulations and guidelines remain a major market challenge, as manufacturers must comply with demanding requirements related to quality systems, validation, documentation, manufacturing practices, and clinical safety.

• High production costs, biosafety and biosecurity considerations, and ethical concerns represent additional constraints, particularly for complex therapeutic applications and advanced synthetic biology workflows.

• Emerging markets offer significant growth opportunities, as biotechnology research, academic funding, healthcare infrastructure, and genomics capabilities continue to expand across developing economies.

Key Company Profiles

• Thermo Fisher Scientific
• LGC Biosearch Technologies
• Integrated DNA Technologies
• Bioneer
• Eurogentec
• Azenta Life Sciences
• Eurofins Genomics
• Maravai LifeSciences
• GenScript
• Twist Bioscience

For more details, please visit: https://apeloconsulting.com/product/global-oligonucleotide-synthesis-market-and-forecast-to-2032/

Data Source

Apelo Consulting employs comprehensive primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by Apelo Consulting dedicated team of qualified professionals with deep industry experience and expertise.